AC Immune SA (ACIU): Price and Financial Metrics
ACIU Price/Volume Stats
| Current price | $3.68 | 52-week high | $5.14 |
| Prev. close | $3.46 | 52-week low | $2.20 |
| Day low | $3.46 | Volume | 91,705 |
| Day high | $3.69 | Avg. volume | 398,378 |
| 50-day MA | $3.43 | Dividend yield | N/A |
| 200-day MA | $3.50 | Market Cap | 363.95M |
ACIU Stock Price Chart Interactive Chart >
AC Immune SA (ACIU) Company Bio
AC Immune SA, a clinical stage Swiss-based biopharmaceutical company, focuses on neurodegenerative diseases with three product candidates in clinical trials. It designs, discovers, and develops therapeutic and diagnostic products intended to prevent and modify diseases caused by mis-folding proteins. The company was founded in 2003 and is based in Lausanne, Switzerland.
Latest ACIU News From Around the Web
Below are the latest news stories about AC IMMUNE SA that investors may wish to consider to help them evaluate ACIU as an investment opportunity.
AC Immune Announces Pricing of Underwritten Offering of Common SharesAC Immune Announces Pricing of Underwritten Offering of Common Shares Lausanne, Switzerland, December 15, 2023 – AC Immune SA (Nasdaq: ACIU) (the “Company” or “AC Immune”), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that it has priced an underwritten offering of 14.3 million of its common shares at a price of USD 3.50 per share. The Company expects the gross proceeds from the offering, before deducting the underwriting |
AC Immune’s Targeted Anti-pTau Active Immunotherapy for Alzheimer’s Disease Advances into Phase 2b TrialAC Immune’s Targeted Anti-pTau Active Immunotherapy for Alzheimer’s Disease Advances into Phase 2b Trial Potentially registration-enabling Phase 2b study (ReTain) will evaluate the effect of ACI-35.030 on cognition and Tau pathology in approximately 500 participants with preclinical Alzheimer’s disease (AD)Anti-pTau active immunotherapy being designed to potentially prevent or reduce cognitive decline could address need of over 315 million people globally1 with preclinical ADAC Immune to receive |
AC Immune SA's (NASDAQ:ACIU) top owners are private equity firms with 37% stake, while 25% is held by individual investorsKey Insights Significant control over AC Immune by private equity firms implies that the general public has more power... |
The Zacks Analyst Blog Highlights Biogen, Prothena, AC Immune's and VaxxinityBiogen, Prothena, AC Immune's and Vaxxinity are part of the Zacks top Analyst Blog. |
Alzheimer's Disease Space Evolves in 2023: Stocks in FocusThe approval of the breakthrough treatment Leqembi for Alzheimer's Disease has put this space in the spotlight. Companies like ACIU, VAXX and PRTA are in focus, given their experimental vaccines. |
ACIU Price Returns
| 1-mo | 7.92% |
| 3-mo | -10.02% |
| 6-mo | 19.87% |
| 1-year | 22.26% |
| 3-year | -47.35% |
| 5-year | -31.73% |
| YTD | -26.40% |
| 2023 | 145.10% |
| 2022 | -58.79% |
| 2021 | -4.26% |
| 2020 | -39.32% |
| 2019 | -9.84% |
Continue Researching ACIU
Want to see what other sources are saying about AC Immune SA's financials and stock price? Try the links below:AC Immune SA (ACIU) Stock Price | Nasdaq
AC Immune SA (ACIU) Stock Quote, History and News - Yahoo Finance
AC Immune SA (ACIU) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...